MBIO

Mustang Bio, Inc. (ticker: MBIO) is a clinical-stage biopharmaceutical company based in Worcester, Massachusetts, dedicated to advancing innovative cell and gene therapies targeting hematologic cancers, solid tumors, and rare genetic disorders. The company is focused on developing a robust pipeline that leverages cutting-edge technologies with the potential for curative outcomes. Committed to tackling significant unmet medical needs, Mustang Bio strives to transform the treatment landscape through strategic collaborations and a strong emphasis on gene editing innovation, positioning itself as a key player in the biotherapeutics industry.